SU5416 in Patients With AIDS-Related Kaposi's Sarcoma Who Have Not Responded to Treatment

This study has been completed.

First Received: June 30, 2000 Last Updated: June 23, 2005 History of Changes

Sponsor:	SUGEN
Information provided by:	NIH AIDS Clinical Trials Information Service
ClinicalTrials.gov Identifier:	NCT00005931

Purpose

The purpose of this study is to test the effectiveness of SU5416 in patients with AIDS-related Kaposi's sarcoma (KS).

Condition	Intervention	Phase
Sarcoma, Kaposi HIV Infections	Drug: SU5416	Phase II

Study Type:	Interventional
Study Design:	Treatment, Efficacy Study
Official Title:	A Multicenter, Open-Label, Phase II Study of SU5416 in Patients With Therapy-Refractory Cutaneous AIDS-Related Kaposi's Sarcoma

Resource links provided by NLM:

MedlinePlus related topics: AIDS Cancer Kaposi's Sarcoma Soft Tissue Sarcoma

Drug Information available for: Semaxanib SU 5416

U.S. FDA Resources

Further study details as provided by NIH AIDS Clinical Trials Information Service:

Estimated Enrollment:

Detailed Description:

Patients are given SU5416 via twice-weekly intravenous infusions in 4-week treatment cycles. Any patient who has not experienced unacceptable toxicity and who is deemed to be responding to the study drug (no evidence of disease progression) is permitted to continue receiving SU5416 in 4-week treatment cycles (up to a maximum of 1 year of therapy) until that patient experiences either unacceptable toxicity or tumor progression, as defined in the protocol.

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria

Patients may be eligible for this study if they:

Are at least 18 years old.
Have KS.
Have taken paclitaxel, DaunoXome, or Doxil for KS and they have either not gotten better or could not tolerate treatment therapy.
Have 1 of the following symptoms for KS: 5 lesions (sores), generalized KS-related edema (swelling) without sores, or KS-related edema of the arms and legs.
Agree to use an effective method of birth control during the study.

Exclusion Criteria

Patients will not be eligible for this study if they:

Are pregnant or breast-feeding.
Are allergic to Cremophor.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00005931

Locations

United States, California
Alison L. Hannah
South San Francisco, California, United States, 94080

Sponsors and Collaborators

SUGEN

More Information

No publications provided

Study ID Numbers:	310B, SU5416.027
Study First Received:	June 30, 2000
Last Updated:	June 23, 2005
ClinicalTrials.gov Identifier:	NCT00005931 History of Changes
Health Authority:	United States: Food and Drug Administration

Keywords provided by NIH AIDS Clinical Trials Information Service:

Skin Neoplasms
Sarcoma, Kaposi
Acquired Immunodeficiency Syndrome
Antineoplastic Agents

Enzyme Inhibitors
SU 5416
Protein-Tyrosine Kinase

Additional relevant MeSH terms:

Sexually Transmitted Diseases, Viral
Slow Virus Diseases
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Physiological Effects of Drugs
Infection
Protein Kinase Inhibitors
Neoplasms, Connective and Soft Tissue
Therapeutic Uses
Neoplasms, Vascular Tissue
Growth Inhibitors
Angiogenesis Modulating Agents
Retroviridae Infections
RNA Virus Infections
Neoplasms by Histologic Type

Immune System Diseases
Growth Substances
Sarcoma, Kaposi
Acquired Immunodeficiency Syndrome
Enzyme Inhibitors
Angiogenesis Inhibitors
Pharmacologic Actions
Immunologic Deficiency Syndromes
SU 5416
Herpesviridae Infections
Virus Diseases
Neoplasms
HIV Infections
Sexually Transmitted Diseases
Lentivirus Infections

ClinicalTrials.gov processed this record on November 27, 2009